Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dow Spin-Off Pfenex Inks Licensing Pact With Merck For Its Protein Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

The big drug maker will pay as much as $52 million to tap protein expression technology used to make proteins for developing a vaccine candidate.

You may also be interested in...



Merck Sprints Toward Late 2020 Filing For Pneumococcal Vaccine V114

Merck’s 15-valent vaccine candidate was non-inferior to Pfizer’s Prevnar 13 in a Phase III study and provided superior protection against serotype 3, a frequent cause of invasive pneumococcal disease. 

Next-Gen Pneumococcal Vaccine Race Continues With Merck’s V114 Data

Merck’s V114 protected against all 15 targeted serotypes in the first two of 16 Phase III studies, but market leader Pfizer’s 20-valent Prevnar 13 successor is on track for a US FDA filing in late 2020.

Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy

With the acquisition, Merck gains a contract manufacturing organization with specific expertise in microbial-derived biologics.

Related Content

Topics

UsernamePublicRestriction

Register

PS068868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel